Phase II study of intermediate-dose cytarabine in patients with relapsed or refractory ewing sarcoma: A report from the children's oncology group

Pediatric Blood and Cancer

Volumn 52, Issue 3, 2009, Pages 324-327

  Dubois, Steven G ^a   Krailo, Mark D ^b,c   Lessnick, Stephen L ^d   Smith, Richard ^d   Chen, Zhengjia ^b   Marina, Neyssa ^e   Grier, Holcombe E ^f   Stegmaier, Kimberly ^f  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b CHILDREN S ONCOLOGY GROUP   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^e STANFORD UNIVERSITY   (United States)

^f BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

Cytarabine; Ewing sarcoma; EWS FLI1

Indexed keywords

CORTICOSTEROID; CYTARABINE; GEMCITABINE; SODIUM CHLORIDE; VANCOMYCIN; ANTINEOPLASTIC AGENT;

ADD ON THERAPY; ADOLESCENT; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BACTEREMIA; BLOOD TOXICITY; CANCER RELAPSE; CELLULITIS; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CONJUNCTIVITIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; ESCHERICHIA COLI INFECTION; EWING SARCOMA; FEBRILE NEUTROPENIA; FEMALE; HISTOLOGY; HUMAN; HYPOALBUMINEMIA; KLEBSIELLA INFECTION; MALE; MULTIPLE CYCLE TREATMENT; MYOSITIS; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PHOTOPHOBIA; PRIORITY JOURNAL; RECURRENT CANCER; SCHOOL CHILD; SIDE EFFECT; THORAX PAIN; THROMBOCYTOPENIA; TREATMENT RESPONSE; ONCOLOGY; PATHOLOGY; TREATMENT OUTCOME;

ADOLESCENT; ADULT; ANTINEOPLASTIC AGENTS; CHILD; CYTARABINE; HUMANS; MEDICAL ONCOLOGY; SARCOMA, EWING'S; TREATMENT OUTCOME;

EID: 58949100145     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.21822     Document Type: Article

References (19)

1. Gurney JG, Swensen AR, Bulterys M. Malignant bone tumors. In: Ries L, Smith M, Gurney JG, et al., editors. Cancer incidence and survival among children and adolescents: United States SEER Program 1975-1995. Bethesda: National Cancer Institute; 1999. pp. 99-110.
2. Delattre O, Zucman J, Plougastel B, et al. Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours. Nature 1992;359:162-165.
3. Turc-Carel C, Aurias A, Mugneret F, et al. Chromosomes in Ewing's sarcoma. I. An evaluation of 85 cases of remarkable consistency of t(11;22)(q24;q12). Cancer Genet Cytogenet 1988; 32:229-238.
4. Johnson SA. Clinical pharmacokinetics of nucleoside analogues: Focus on haematological malignancies. Clin Pharmacokinet2000; 39:5-26.
5. Hofbauer S, Hamilton G, Theyer G, et al. Insulin-like growth factor-I-dependent growth and in vitro chemosensitivity of Ewing's sarcoma and peripheral primitive neuroectodermal tumour cell lines. Eur J Cancer 1993;29A:241-245.
6. Stegmaier K, Wong JS, Ross KN, et al. Signature-based small molecule screening identifies cytosine arabinoside as an EWS/FLI modulator in Ewing sarcoma. PLoS Med 2007;4:e122.
7. Bacci G, Ferrari S, Longhi A, et al. Therapy and survival after recurrence of Ewing's tumors: The Rizzoli experience in 195 patients treated with adjuvant and neoadjuvant chemotherapy from 1979 to 1997. Ann Oncol 2003;14:1654-1659.
8. Barker LM, Pendergrass TW, Sanders JE, Hawkins DS. Survival after recurrence of Ewing's sarcoma family of tumors. J Clin Oncol 2005;23:4354-4362.
9. Rodriguez-Galindo C, Billups CA, Kun LE, et al. Survival after recurrence of Ewing tumors: The St Jude Children's Research Hospital experience, 1979-1999. Cancer 2002;94:561-569.
10. Shankar AG, Ashley S, Craft AW, Pinkerton CR. Outcome after relapse in an unselected cohort of children and adolescents with Ewing sarcoma. Med Pediatr Oncol 2003;40:141-147.
11. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-216.
12. Chang MN, O'Brien PC. Confidence intervals following group sequential tests. Control Clin Trials 1986;7:18-26.
13. Chang MN, Therneau TM, Wieand HS, Cha SS. Designs forgroup sequential phase II clinical trials. Biometrics 1987;43:865-874.
14. Ishii E, Hara T, Ohkubo K, et al. Treatment of childhood acute lymphoblastic leukemia with intermediate-dose cytosine arabino- side and adriamycin. Med Pediatr Oncol 1986;14:73-77.
15. Plunkett W, Liliemark JO, Adams TM, et al. Saturation of 1-beta- D-arabinofuranosylcytosine 5'-triphosphate accumulation in leukemia cells during high-dose 1-beta-D-arabinofuranosylcytosine therapy. Cancer Res 1987;47:3005-3011.
16. Takashima Y, Matsuyama K. Pharmacokinetic studies of intermediate-to high-dose 1-beta-D-arabinofuranosylcytosine in children with acute leukemia and lymphoma. J Clin Pharmacol 1987; 27:330-333.
17. Tebbi CK, Krischer J, Fernbach DJ, et al. Toxicity of high-dose cytosine arabinoside in the treatment of advanced childhood tumors resistant to conventional therapy. A Pediatric Oncology Group study. Cancer 1990;66:2064-2067.
18. Navid F, Willert JR, McCarville MB, et al. Combination of gemcitabine and docetaxel in the treatment of children and young adults with refractory bone sarcoma. Cancer 2008.
19. Wagner-Bohn A, Paulussen M, Vieira Pinheiro JP, et al. Phase II study of gemcitabine in children with solid tumors of mesenchymal and embryonic origin. Anticancer Drugs 2006;17:859-864.